← All Sponsors
SPONSOR

Cullinan Therapeutics Inc.

Total Trials
2
Recruiting
2
Phases
Phase 1
Conditions studied: SLESLE (Systemic Lupus)Relapsed/Refractory Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS)
NCT06613360 Phase 1
Recruiting

A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus

SLE
United States, Australia, Bulgaria View Trial →
NCT05143996 Phase 1
Recruiting

CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Relapsed/Refractory Acute Myeloid Leukemia (AML)
United States View Trial →